Search

Search bills, members, committees and pages...

H.R. 3037

U.S. HouseIn House Committee

Summary

H.R. 3037, the Access to Breast Cancer Diagnosis Act of 2025, was introduced in the House on Apr 28, 2025 by Rep. Debbie Dingell (D) with 59 co-sponsors. It was referred to Energy And Commerce, and last saw action on Apr 28, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


Record

Text

H.R. 3037 has 59 co-sponsors.

hb3037/introduced-in-house.txt
119 HR 3037 IH: Access to Breast Cancer Diagnosis Act of 2025
U.S. House of Representatives
2025-04-28
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I
119th CONGRESS 1st Session
H. R. 3037
IN THE HOUSE OF REPRESENTATIVES
April 28, 2025
Mrs. Dingell (for herself, Mr. Fitzpatrick , and Ms. Wasserman Schultz ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations.
1.
Short title
This Act may be cited as the Access to Breast Cancer Diagnosis Act of 2025 .
2.
Requiring diagnostic and supplemental breast examinations to be covered with no cost-sharing requirements
(a)
In general
Subpart II of part A of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–11 et seq. ) is amended by adding at the end the following new section:
2730.
Diagnostic and supplemental breast examinations
(a)
In general
In the case of a group health plan, or a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to diagnostic and supplemental breast examinations furnished to an individual enrolled under such plan or such coverage, such plan or coverage shall not impose any cost-sharing requirements for these benefits.
(b)
Construction
Nothing in this section shall be construed—
(1)
to prohibit a group health plan or health insurance issuer from requiring timely prior authorization or imposing other appropriate utilization controls in approving coverage for any diagnostic and supplemental breast examination; or
(2)
to supersede a State law that provides greater protections with respect to the coverage of diagnostic and supplemental breast examinations than is provided under this section.
(c)
Definitions
In this section:
(1)
Cost-sharing requirements
The term cost-sharing requirements means a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment or similar out-of-pocket expense.
(2)
Diagnostic breast examination
The term diagnostic breast examination means a medically necessary and appropriate (in accordance with National Comprehensive Cancer Network Guidelines) examination of the breast (including, but not limited to such an examination using diagnostic mammography, breast magnetic resonance imaging, or breast ultrasound) that is—
(A)
used to evaluate an abnormality seen or suspected from a screening examination for breast cancer; or
(B)
used to evaluate an abnormality detected by another means of examination.
(3)
Supplemental breast examinations
The term supplemental breast examination means a medically necessary and appropriate (in accordance with National Comprehensive Cancer Network Guidelines) examination of the breast (including, but not limited to such an examination using breast magnetic resonance imaging or breast ultrasound) that is—
(A)
used to screen for breast cancer when there is no abnormality seen or suspected; and
(B)
furnished based on personal or family medical history or additional factors that may increase the individual’s risk of breast cancer.
.
(b)
Application to grandfathered health plans
Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18011(a)(4)(A) ) is amended—
(1)
by striking title and inserting title, or as added after the date of the enactment of this Act ; and
(2)
by adding at the end the following new clause:
(v)
Section 2730 (relating to coverage for diagnostic and supplemental breast examinations).
.
(c)
Application to high deductible health plans with health savings account eligibility
Section 223(c)(2) of the Internal Revenue Code of 1986 is amended by adding at the end the following:
(H)
Safe harbor for absence of deductible for diagnostic and supplemental breast examinations
In the case of plan years beginning on or after January 1, 2026, a plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for diagnostic and supplemental breast examinations.
.
(d)
Effective date
The amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2026.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-04-28
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations.

Sponsors

Rep. Debbie Dingell (D) sponsors H.R. 3037, and 59 members have co-sponsored it, 2 of them from the day it was introduced.

Committees

H.R. 3037 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means
Ways and Means
Referred To · Apr 28, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Apr 28, 2025 · 1,636 Bills

Actions

H.R. 3037 has taken 2 actions since Apr 28, 2025.

ChamberAction
Apr 28, 2025
House
Introduced in House
Apr 28, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 3037 has not gone to a roll call.

1 bill is related to H.R. 3037, as Identical bill.

Titles

H.R. 3037 goes by 3 titles, 1 of them short titles.

  • Access to Breast Cancer Diagnosis Act of 2025 — Display Title
  • Access to Breast Cancer Diagnosis Act of 2025 — Short Title(s) as Introduced
  • To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations. — Official Title as Introduced

Lobbying

7 clients hired 7 firms and 37 registered lobbyists who named H.R. 3037 in 32 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Budget/Appropriations, Medicare/Medicaid, Taxation/Internal Revenue Code, Insurance, Copyright/Patent/Trademark, Trade (domestic/foreign), Medical/Disease Research/Clinical Labs.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
NOVARTISDistrict of Columbia17
SUSAN G. KOMENorganization addressing breast cancer through research, community health, public policyTexas15$200K
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCDistrict of Columbia15
GE HEALTHCARE TECHNOLOGIES INC.Global medical technology, pharmaceutical diagnostics and digital solutions company.Illinois15
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMENTexas15
HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC.New York13
NOVARTIS, INC.Multinational biopharmaceutical companyDistrict of Columbia12$100K

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 37.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
NOVARTISNOVARTIS2026 first_quarter$3.9M1st Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 second_quarter$2.6M2nd Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 fourth_quarter$2.4M4th Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2026 first_quarter$2.3M1st Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2025 third_quarter$2.1M3rd Quarter - Report
NOVARTISNOVARTIS2025 third_quarter$1.7M3rd Quarter - Amendme…
NOVARTISNOVARTIS2025 third_quarter$1.6M3rd Quarter - Report
NOVARTISNOVARTIS2026 second_quarter$1.4M2nd Quarter - Report
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INCAMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.2026 second_quarter$1.2M2nd Quarter - Report
NOVARTISNOVARTIS2025 fourth_quarter$1M4th Quarter - Report
NOVARTISNOVARTIS2025 second_quarter$920K2nd Quarter - Amendme…
NOVARTISNOVARTIS2025 second_quarter$880K2nd Quarter - Report
GE HEALTHCARE TECHNOLOGIES INC.GE HEALTHCARE TECHNOLOGIES INC.2026 first_quarter$700K1st Quarter - Report
GE HEALTHCARE TECHNOLOGIES INC.GE HEALTHCARE TECHNOLOGIES INC.2025 fourth_quarter$380K4th Quarter - Report
GE HEALTHCARE TECHNOLOGIES INC.GE HEALTHCARE TECHNOLOGIES INC.2025 third_quarter$370K3rd Quarter - Report
GE HEALTHCARE TECHNOLOGIES INC.GE HEALTHCARE TECHNOLOGIES INC.2026 second_quarter$350K2nd Quarter - Report
GE HEALTHCARE TECHNOLOGIES INC.GE HEALTHCARE TECHNOLOGIES INC.2025 second_quarter$350K2nd Quarter - Report
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMENTHE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN2025 second_quarter$240K2nd Quarter - Report
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMENTHE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN2026 second_quarter$130K2nd Quarter - Report
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMENTHE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN2026 first_quarter$80K1st Quarter - Report

Classification

The Congressional Research Service files H.R. 3037 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 3037’s is Health.

hr3037/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 3037, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 70 (Monday, April 28, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. DINGELL:H.R. 3037.Congress has the power to enact this legislation pursuantto the following:The Constitutional authority of Congress to enact thislegislation is provided by Article 1, Section 8 of the UnitedStates Constitution.[Page H1684]

Source: congress.gov · legiscan.com